While the two countries have traditionally sparred on the intellectual property rights (IPR) regime in the pharmaceuticals sector, India must learn the right lessons from the US President Donald Trump\u2019s warnings over the weekend. The Trump regime is aggressively redrawing the global trade map with \u201cAmerica first\u201d as its compass\u2014it has just labelled Indian food subsidies trade-distorting at the WTO. But, while continuing to fight the US on important matters, India needs to pick its battles and, in other cases, forge alliances with the US since the areas of commonality are greater than the areas of differences. Given just how few Indians were actually affected, did the government really need to put price caps on stents\u2014an industry report shows that the stent-price capping has not had a significant impact in terms of costs of angioplasties falling or even in terms of number of angioplasties taking place. Indeed, when Trump said the caps delay "the availability of new cures to patients living in countries implementing these policies", he was correct, since US stent major Abbott has already withdrawn a "resorbable" and drug-eluting stent from the Indian market; indeed, this has sent unfortunate signals about India\u2019s regulatory approach. Similarly, unmindful of the number of people\u2014a few thousand\u2014affected by Bayer\u2019s liver and kidney cancer drug Nexavar, India issued a compulsory license in 2012 which essentially destroyed Bayer\u2019s monopoly, and ensured India came in for a lot of criticism from the US; a far simpler solution would have been to negotiate special prices with Bayer. Not only did India realise its mistake and give the US an informal assurance that it would not use compulsory licensing again, it did not act when, in 2015, a parliamentary committee recommended that 509 drug formulations be brought under compulsory licensing. Also, while it is true that the US and India are sparring on Section 3(d) of the Indian Patents Act, that prevents the US\u2014style ever-greening of patents, India is on strong grounds in that its patent law is WTO-compatible. But, while India and the US disagree on pharmaceuticals IP laws when Indian firms are also creating their own IP, strong laws benefit India as well. A FICCI paper by the Thought and Arbitrage Research Institute a few years ago put the loss in seven major industries\u2014and this did not include pharma\u2014due to counterfeiting and trademark\/patent violations at `72,000 crore in FY12, and `100,000 crore in FY14. Indeed, this is why the industry ministry had put out a discussion paper on a modern IP law which includes having special IPR courts\u2014little came of this, though. Similarly, though not related to pharma, had the government not adopted an anti-Monsanto stand\u2014especially since this helps Indian farmers\u2014 this would have helped assuage the US\u2019 feelings.